TREATMENT PARADIGM

First-line maintenance therapy for patients with gBRCA-mutated* metastatic pancreatic cancer whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy1

A targeted approach to help maintain first-line progression-free survival1

*gBRCAm should be determined by an FDA-approved companion diagnostic for LYNPARZA.1

Pancreatic Cancer Treatment Paradigm Graphic
First Step in Treatment Paradigm

As recommended by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), all patients with confirmed pancreatic cancer should receive genetic testing for inherited mutations, including gBRCAm, at diagnosis to help inform therapy2

Second Step in Treatment Paradigm

Treat gBRCA-mutated mPaC with first-line platinum-based chemotherapy1

Third Step in Treatment Paradigm

Actively maintain with LYNPARZA1

*gBRCAm should be determined by an FDA-approved companion diagnostic for LYNPARZA.1

Pancreatic Cancer Treatment Paradigm Graphic

NCCN Guidelines® NCCN Category 1 and 2A recommendations for platinum-based chemotherapy in metastatic pancreatic adenocarcinoma2

Platinum-based chemotherapy is a preferred regimen for first-line treatment of patients with metastatic pancreatic cancer with good performance status (ECOG PS 0-1) and known BRCA1/2 or PALB2 mutations:

  • FOLFIRINOX (Category 1)
  • Modified FOLFIRINOX (Category 2A)
  • Gemcitabine + cisplatin (Category 2A)
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

ASCO®

Metastatic Pancreatic Cancer: ASCO Guideline Update7

  • Recommendation 3.3. In patients who have a germline BRCA1 or BRCA2 mutation and who have received first-line platinum-based chemotherapy without disease progression for at least 16 weeks, options for continued treatment include chemotherapy or PARP inhibitor olaparib (Type: evidence based; benefits outweigh harms; evidence quality: low; strength of recommendation: moderate)
  • Qualifying statement. For the group of platinum-sensitive patients included in Recommendation 3.3, the decision to continue treatment with chemotherapy or proceed to maintenance therapy with olaparib should be based on a discussion between the patient and the oncologist, including consideration of whether a maximum response and plateau in response to chemotherapy have been achieved, the level of cumulative toxicities associated with chemotherapy treatment, patient preference, convenience, toxicity, goals of care, cost, and clinical evidence, including a lack of overall survival benefit demonstrated in the POLO randomized controlled trial